Abstract:Introduction: Liver transplantation (LT) is a life-saving procedure that resolves complications of cirrhosis. However, the metabolic risk factors for nonalcoholic fatty liver disease (NAFLD) persist and potentially worsen in the post-transplant setting, thereby increasing the risk of liver fibrosis. Liver biopsy is the gold standard to diagnose NAFLD and liver fibrosis, but this procedure is invasive and less than ideal for longitudinal monitoring after LT. We aimed to investigate the association of serum steatosis and fibrosis biomarkers with mortality and graft loss in LT recipients. Methods: We included consecutive adults who received a liver transplant at the MUHC in 2014-2021 and were followed up annually. The outcomes measured were death and graft loss, graft loss being defined as graft failure leading to death or re-transplantation. We assessed the prognostic value of the biomarkers ALT, AST, GGT, AST-to-Platelet Ratio Index (APRI), fibrosis-4 index (FIB-4), and hepatic steatosis index (HSI). Hepatic steatosis was defined as HSI >36, and liver fibrosis was characterized as FIB-4 > 3.64 or APRI > 1. Survival analysis and Generalized Estimating Equation (GEE) models were used to assess the association between the biomarkers and the outcomes. Results: Two hundred nineteen patients were followed for 30 months on average. Graft loss and mortality occurred in 12 patients (9%) and 38 (29.5%) resulting in incidence rates of 29.5 (95% CI 20.9-40.6) and 9.6 (95% CI 5-16.8) per 100 person-years, respectively. Patients who died during the follow-up were older, had an older donor, and had a history of diabetes. On multivariable analysis using the GEE model (see Table 1), higher ALT and higher AST were associated with mortality after adjustment for sex, BMI, age, albumin, and platelets. In the time-to-event analysis, the Kaplan Meier curves showed that APRI >1 could be a potential predictor of mortality (P = 0.0729 see Figure 1). Neither FIB-4 (log-rank, P = 0.199) nor HSI (log-rank, P = 0.919) were associated with mortality. None of the biomarkers or liver transaminases were associated with graft loss. Conclusion: Liver transaminases and the serum fibrosis biomarker APRI are associated with mortality in LT recipients. The hepatic steatosis biomarker HSI does not seem to be valuable in predicting outcomes in this population. None among liver transaminases, steatosis or fibrosis biomarkers predicted graft loss. Table 1. - GEE of liver transaminases on death in LT patients Characteristics Univariate Multi-Variate * Odds Ratio 95% CI P-value Odds Ratio 95% CI P-value ALT Moderate/Severe 0.9999 0.9999–1.0000 0.0931 1.0001 1.0000–1.0002 0.0040 AST Moderate/Severe 1.0000 0.9999–1.0000 0.3934 1.0001 1.0000–1.0001 0.0037 ALP Moderate/Severe 0.9999 0.9996–1.0001 0.2807 1.0000 0.9998–1.0001 0.6113 GGT Moderate/Severe 0.9998 0.9996–1.0000 0.0236 0.9998 0.9997–1.0000 0.0596 Smoking status No 1.00 1.00 Yes 0.921 0.71–1.20 0.5444 0.934 0.74–1.18 0.5649 *multivariate models are adjusted for age, sex, albumin, BMI and platelets. Figure 1.: Kaplan-Meier survival curve in LT patients according to the APRI biomarker.

Protocol liver biopsy predicts graft survival after liver transplantation

Utility of protocol biopsy in renal recipients: Meta analysis and systematic review

Pathologic Diagnosis of Transplantation Liver Puncture Biopsy: Histopathologic Analysis of 98 Cases

Short-term and long-term outcomes of liver transplantation using moderately and severely steatotic donor livers: A systematic review.

Clinical Significance of Protocol Biopsy at One Month Posttransplantation in Deceased-Donor Renal Transplantation

Value of Pretransplant Albumin-Bilirubin Score in Predicting Outcomes after Liver Transplantation

Postreperfusion Renal Allograft Biopsy Predicts Outcome of Single-Kidney Transplantation: A 10-Year Observational Study in China

Liver Biopsy in Evaluation of Complications Following Liver Transplantation

Serum Fibrosis and Steatosis Biomarkers for the Prediction of Mortality in Liver Transplant Recipients

The Value of Liver Biopsy for Pathological Diagnosis in Liver Transplant Patients

The Predictive Value of Graft Viability and Bioenergetics Testing Towards the Outcome in Liver Transplantation

Comparison of Urinary Liver Fatty Acid Binding Protein Level and Pathologic Biopsy Findings 1 Year After Kidney Transplantation

Prognostic Value of Protein Biomarkers in Liver Transplantation: A Systematic Review

Liver Biopsy in the Management of Liver Dysfunction after Allogeneic Hematopoietic Stem-Cell Transplantation

Donation After Cardiac Death Liver Transplantation: Graft Quality Evaluation Based On Pretransplant Liver Biopsy

Analysis on Pathological Data of Liver Biopsies after Orthotopic Liver Transplantation

Regular protocol liver biopsy is useful to adjust immunosuppressant dose after adult liver transplantation

Routine early biopsy of allografts with delayed function: correlation of histopathology and transplant outcome

Incidence, epidemiology and outcomes of acute allograft rejection following liver transplantation in Australia

[Analysis of 565 Cases of Liver Transplantation at a Single Transplantation Center].

Clinical Analysis and Proteomic Screening Biomarkers for Graft-Versus-Host Disease After Liver Transplant